Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Hospira Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (283)
Cancellation by sponsor (53)

Date

2025 (8)
2024 (12)
2023 (7)
2022 (9)
2021 (30)
2020 (31)
2019 (28)
2018 (1)
2017 (5)
2016 (5)
2015 (4)
2014 (7)
2013 (14)
2012 (1)
2011 (10)
2010 (2)
2009 (16)
2008 (23)
2007 (61)
2006 (7)
2005 (23)
2004 (9)
2001 (2)
2000 (2)
1998 (3)
1997 (4)
1996 (1)
1994 (4)
1992 (4)
1991 (3)

Search

Sponsor content

336 result(s) found, displaying 81 to 90

Hospira Doxorubicin Hydrochloride for Injection, USP 10 mg vial Cancelled under Section 30(1)(c) of the Act

17 December 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Doxorubicin Hydrochloride for Injection, USP 50 mg vial Cancelled under Section 30(1)(c) of the Act

17 December 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Doxorubicin Hydrochloride10 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

17 December 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Calcium Folinate Injection 50 mg/5 mL vial (309207)

12 September 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Hospira Calcium Folinate Injection 50 mg/5 mL vial.
Hospira Australia Pty Ltd - Medicine administration kit, percutaneous, non-medicated, reusable Cancelled under Section 41GL(d) of the Act

3 December 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL CYTARABINE 100mg/1mL injection vial Cancelled under Section 30(1)(c) of the Act

2 November 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL CYTARABINE 500mg/5mL injection vial Cancelled under Section 30(1)(c) of the Act

2 November 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL FLUOROURACIL fluorouracil 1g/20mL injection BP vial Cancelled under Section 30(1)(c) of the Act

6 October 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL GENTAMICIN 80mg/2mL (as sulfate) injection BP vial Cancelled under Section 30(1)(c) of the Act

1 October 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL SODIUM NITROPRUSSIDE FOR INJECTION Sodium nitroprusside 50mg powder for injection BP vial Cancelled under Section 30(1)(c) of the Act

1 October 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.